| 2022 | | A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer | 공태욱, 장석준 |
| 2018 | | A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2018 | | ASGO 5th International Workshop on Gynecologic Oncology | 손주혁, 유희석, 장석준 |
| 2024 | | Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines | 손주혁, 장석준 |
| 2019 | | Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2023 | | Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01) | 장석준 |
| 2024 | | Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go? | 장석준 |
| 2023 | | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | 장석준 |
| 2023 | | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis | 손주혁, 장석준 |
| 2024 | | Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study | 공태욱, 손주혁, 장석준 |
| 2023 | | Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001) | 공태욱, 손주혁, 장석준 |
| 2018 | | Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement | 장석준 |
| 2020 | | Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer | 이진구 |
| 2020 | | Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial | 장석준 |
| 2018 | | Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery | 공태욱, 백지흠, 손주혁, 유희석, 장석준 |
| 2023 | | Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004) | 공태욱, 김지연, 손주혁, 장석준 |
| 2023 | | Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer | 공태욱, 김지연, 손주혁, 장석준 |
| 2024 | | Surgery for Recurrent Epithelial Ovarian Cancer | 장석준 |
| 2022 | | Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial | 장석준 |
